Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) Antibody

1274€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx179031
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) |
Host | Mouse |
Reactivity | Human |
Recommended Dilution | WB: 1/40 - 1/400, IHC: 1/40 - 1/200, IF/ICC: 1/40 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Monoclonal |
Conjugation | Unconjugated |
Expression | Recombinant |
Purification | Purified by Protein A and Protein G affinity chromatography. |
Size 1 | 1 ml |
Form | Liquid |
Tested Applications | WB, IHC, IF/ICC |
Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
Availability | Please enquire. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
Alias | Tumor necrosis factor receptor superfamily member 9,ILA,4-1BB,CD137,CDw137,IMD109,4-1BB ligand receptor,T-cell antigen 4-1BB homolog,T-cell antigen ILA |
Background | Antibody anti-TNFRSF9 |
Status | RUO |
Descripción
TNFRSF9, also known as 4-1BB or CD137, is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays a key role in immune regulation. This receptor is expressed primarily on activated T cells, as well as on natural killer (NK) cells, dendritic cells, and some other immune cell types, particularly after stimulation. It serves as a co-stimulatory receptor, enhancing T-cell proliferation, survival, and effector function, making it pivotal in immune responses and antitumor immunity. TNFRSF9 has gained attention as a therapeutic target in cancer immunotherapy due to its role in enhancing immune cell activation and persistence. Upon binding with its ligand, TNFSF9 (also known as 4-1BB ligand or 4-1BBL), TNFRSF9 undergoes trimerization, which is essential for transmitting downstream signaling. This receptor’s functions extend beyond tumor immunity; it is also involved in chronic inflammation and autoimmune diseases, and as such, modulation of TNFRSF9 signaling has therapeutic implications across several pathologies.
Related Products

Human TNFRSF9/4-1BB (Tumor necrosis factor receptor superfamily member 9) ELISA Kit
Ver Producto
Human TNFRSF9/4-1BB (Tumor necrosis factor receptor superfamily member 9) ELISA Kit
Ver Producto